Recruiting Multiple Myeloma Studies in Omaha
Selinexor and Backbone Treatments of Multiple Myeloma Patients
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/re...
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)...
About Multiple Myeloma Clinical Trials in Omaha
Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.
There are currently 2 multiple myeloma clinical trials recruiting participants in Omaha, NEBRASKA. These studies are seeking a combined 339 participants. Research is being sponsored by Karyopharm Therapeutics Inc, Oncotherapeutics. Clinical trial participation is free and participants receive study-related medical care at no cost.
Multiple Myeloma Clinical Trials in Omaha — FAQ
Are there multiple myeloma clinical trials in Omaha?
Yes, there are 2 multiple myeloma clinical trials currently recruiting in Omaha, NEBRASKA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Omaha?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Omaha research site will contact you about next steps.
Are clinical trials in Omaha free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Omaha studies also compensate for your time and travel.
What multiple myeloma treatments are being tested?
The 2 active trials in Omaha are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.
Data updated March 2, 2026 from ClinicalTrials.gov